Cosentyx (secukinumab) is a medication that is used to treat various autoimmune conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. According to the sources provided, Cosentyx can be safely used for extended periods of time, although there are some potential side effects that should be monitored.

One study published in Arthritis Research & Therapy [2] followed patients with psoriatic arthritis who were treated with Cosentyx for up to five years. The study found that the medication was generally well-tolerated and effective in treating symptoms. The most common side effects reported were upper respiratory infections and injection site reactions. However, the study also noted that long-term safety data is still limited and further research is needed.

Another study [3] reviewed the safety and efficacy of Cosentyx in treating psoriasis and psoriatic arthritis. The study found that Cosentyx was effective in reducing symptoms and improving quality of life for patients with both conditions. The study also noted that the medication was generally well-tolerated, with the most common side effects being mild to moderate injection site reactions.

According to Drug Patent Watch [1], Cosentyx was approved by the FDA in 2015 and is currently protected by patents that expire in 2033. This suggests that the medication has undergone rigorous testing and has been deemed safe for use by regulatory agencies.

In summary, the sources provided suggest that Cosentyx can be safely used for extended periods of time to treat autoimmune conditions such as psoriasis and psoriatic arthritis. However, like all medications, there are potential side effects that should be monitored. Patients should work closely with their healthcare providers to determine if Cosentyx is the right treatment option for them and to monitor for any potential side effects.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2
[3] https://pubmed.ncbi.nlm.nih.gov/35146532/